While some states ban insurers from using copay accumulator programs, oversight has stalled at the federal level.

Prescription drug costs remain a major concern for millions of Americans in 2026. Fortunately, several federal, state, ...

The 340B Drug Pricing Program may be partly driving U.S. hospital consolidation and worsening affordability for patients, some analysts have warned. Section 340B of the Public Hea ...

Pervasive "unsustainable" clinical practices amid cat-and-mouse game with funding availabi ...

Patients who rely on co-pay assistance from drugmakers are typically heavy users of health care for whom delays in treatment ...

The emergence of Lilly’s bundling strategy for Zepbound and Taltz reflects the unregulated state of patient assistance programs in the commercial market and the need for Congressional intervention. A ...

Thousands of low-income people living with HIV could be losing drug coverage as states impose limitations on HIV assistance programs amid constrained budgets — raising alarms over consistent access to ...